As illustrated in Figure 6(a), SPRR1B inhibition significantly decreased the percentage of cells in the G0/G1 phase (51.67% to 21.02%, p < 0.01 and 53.63% to 28.91%, p < 0.01) and increased the percentage of cells in the G2 phase in both H1650 and H1975 lung adenocarcinoma cell lines (8.078% to 61.09%, p < 0.01 and 38. The gene discussed is SPRR1B; the disease is lung adenocarcinoma.